Docket No.: PF-0069-1 CON

IN THE CLAIMS

This listing of the claims replaces all prior versions of the claims in the application. Note that claims 1-30 have been canceled, without prejudice or disclaimer, and substituted with new claims 31-.

1.-59. (Canceled)

60. (New) An isolated polynucleotide encoding a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1,

b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, said polypeptide having chemotactic activity,

c) a polypeptide comprising a polypeptide fragment, wherein the polypeptide fragment is a fragment of the amino acid sequence of SEQ ID NO:1, said polypeptide fragment having chemotactic activity, and

d) a polypeptide comprising an immunogenic fragment, wherein the immunogenic fragment comprises at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:1.

61. (New) An isolated polynucleotide of claim 60, encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

62. (New) An isolated polynucleotide of claim 61, having the sequence of SEQ ID NO:2.

63. (New) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 60.

64. (New) A cell transformed with a recombinant polynucleotide of claim 63.

PAGE 4/26 * RCVD AT 1/9/2004 5:58:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/2 * DNIS:7465300 * CSID:650 849 8886 * DURATION (mm-ss):09-02

Docket No.: PF-0069-1 CON

65. (New) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to the polynucleotide sequence of SEQ ID NO:2 encoding a polypeptide having chemotactic activity,

c) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide fragment of SEQ ID NO:1 having chemotactic activity,

d) a polynucleotide complementary to the polynucleotide of a),

e) a polynucleotide complementary to the polynucleotide of b), and

f) a polynucleotide complementary to the polynucleotide of c), and

g) an RNA equivalent of a)-f).

66. (New) A method for detecting a target polynucleotide in a sample, the target polynucleotide having a sequence of a polynucleotide of claim 65, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to the target polynucleotide in the sample, and which probe specifically hybridizes to the target polynucleotide, under conditions whereby a hybridization complex is formed between the probe and the target polynucleotide or fragments thereof; and

b) detecting the presence of the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the target polynucleotide in the sample.

67. (New) A method of detecting a target polynucleotide in a sample, the target polynucleotide having a sequence of a polynucleotide of claim 65, the method comprising:

a) amplifying the target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of the amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

PAGE 5/26 * RCVD AT 1/9/2004 5:58:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/2 * DNIS:7465300 * CSID:650 849 8886 * DURATION (mm-ss):09-02

68. (New) A method for producing a polypeptide encoded by a polynucleotide of claim 65, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein the cell is transformed with a recombinant polynucleotide, and the recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide of claim 65; and

b) recovering the polypeptide so expressed.

69. (New) A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of claim 65, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

70. (New) A method of assessing toxicity of a test compound, the method comprising:

a) treating a biological sample containing nucleic acids with the test compound,

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 65 under conditions whereby a specific hybridization complex is formed between the probe and a target polynucleotide in the biological sample, the target polynucleotide comprising a polynucleotide sequence of a polynucleotide of ~~claim 9~~ claim 26 or fragment thereof,

c) quantifying the amount of hybridization complex, and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample indicates potential toxicity of the test compound.

PAGE 6/26 * RCVD AT 1/9/2004 5:58:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/2 * DNIS:7465300 * CSID:650 849 8886 * DURATION (mm-ss):09-02